Gluteus Maximus Transfer for Hip Abductor Insufficiency Following Total Hip Arthroplasty

November 13, 2026 updated by: Ahmed Saeed Younis, Ain Shams University

Clinical and Functional Outcomes of Gluteus Maximus Transfer for the Management of Hip Abductor Insufficiency Following Total Hip Arthroplasty: A Clinical Study

Hip abductor insufficiency is a challenging complication following total hip arthroplasty (THA). It may result from damage to the abductor muscles or tendons, particularly the gluteus medius and minimus, and can lead to persistent hip pain, muscle weakness, a positive Trendelenburg sign, and impaired walking ability.

Gluteus maximus transfer is a surgical procedure used to restore the function of the hip abductor mechanism in patients with severe abductor insufficiency. This study aims to evaluate the clinical and functional outcomes of gluteus maximus transfer in patients who develop abductor insufficiency following total hip arthroplasty.

The study will assess postoperative improvements in hip function, abductor strength, gait, pain, and patient-reported functional outcomes, as well as the occurrence of postoperative complications. The hypothesis is that gluteus maximus transfer can provide meaningful functional improvement in appropriately selected patients with persistent abductor insufficiency following total hip arthroplasty.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

**Inclusion Criteria**

  1. Adult patients aged 18 years or older.
  2. Patients who underwent primary or revision total hip arthroplasty.
  3. Patients with symptomatic hip abductor insufficiency following total hip arthroplasty.
  4. Clinical evidence of abductor mechanism deficiency, including abductor weakness, positive Trendelenburg sign, or gait disturbance.
  5. Patients with irreparable or functionally deficient hip abductor mechanism considered suitable for gluteus maximus transfer.
  6. Availability of preoperative and postoperative clinical and functional assessment data.

**Exclusion Criteria**

  1. Active periprosthetic joint infection at the time of the planned procedure.
  2. Neurological disorders significantly affecting hip abductor function or gait.
  3. Severe gluteus maximus muscle dysfunction or insufficiency that precludes transfer.
  4. Severe medical comorbidities contraindicating surgery.
  5. Inadequate clinical follow-up or missing essential outcome data.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Gluteus Maximus Transfer

Patients with hip abductor insufficiency following total hip arthroplasty undergoing gluteus maximus transfer for reconstruction of the deficient hip abductor mechanism.

Surgical transfer of the gluteus maximus muscle to reconstruct the deficient hip abductor mechanism in patients with persistent abductor insufficiency following total hip arthroplasty. The procedure aims to improve hip abductor function, pelvic stability, gait, and overall functional outcomes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Hip Abductor Muscle Strength
Time Frame: Preoperative assessment and 12 months postoperatively.

Assessment of hip abductor muscle strength before and after gluteus maximus transfer using manual muscle testing according to the Medical Research Council (MRC) grading scale (0-5).

Preoperative assessment and 12 months postoperatively.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional Outcome - Harris Hip Score
Time Frame: preoperative baseline to 12 months postoperatively

Change in Harris Hip Score from preoperative baseline to 12 months postoperatively to assess hip pain and function.

preoperative baseline to 12 months postoperatively
Trendelenburg Sign
Time Frame: preoperative and 12 month postoperative

Assessment of the presence or absence of Trendelenburg sign during clinical examination before and 12 month after surgery.

preoperative and 12 month postoperative
Pain Assessment
Time Frame: preoperative and 12 months postoperative

Change in hip pain intensity measured using the Visual Analog Scale (VAS).

preoperative and 12 months postoperative
Postoperative Complications
Time Frame: during the period of follow up 12 months postoperative

Documentation of postoperative complications, including persistent abductor weakness, infection, dislocation, wound complications, and revision surgery.

during the period of follow up 12 months postoperative

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 30, 2026

Primary Completion (Estimated)

November 30, 2026

Study Completion (Estimated)

November 30, 2026

Study Registration Dates

First Submitted

October 31, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • asy453789

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.